Kwak L W, Thielemans K, Massaia M
National Cancer Institute, Department of Experimental Transplantation and Immunology, Bethesda, MD, USA.
Semin Hematol. 1999 Jan;36(1 Suppl 3):34-7.
Although advances in the treatment of multiple myeloma have been made using high-dose chemotherapy with subsequent autologous stem-cell transplantation, recurrence of the underlying disease almost invariably occurs. One proposed strategy to increase survival is tumor-specific activation of the immune system via idiotypic protein vaccination. Current issues to be resolved in the development of this approach include optimal vaccine formulation, appropriate assays to monitor treatment results, and timing of vaccine administration. Several clinical trials of idiotypic vaccines are currently being conducted in the United States and Europe. Initial results support the use of these vaccines as adjunct therapy in patients with multiple myeloma after high-dose chemotherapy and transplantation.
尽管使用大剂量化疗及随后的自体干细胞移植在多发性骨髓瘤治疗方面取得了进展，但潜在疾病几乎总会复发。一种提高生存率的提议策略是通过独特型蛋白疫苗对免疫系统进行肿瘤特异性激活。这种方法开发中目前有待解决的问题包括最佳疫苗配方、监测治疗结果的合适检测方法以及疫苗给药时间。美国和欧洲目前正在进行多项独特型疫苗的临床试验。初步结果支持将这些疫苗用作多发性骨髓瘤患者大剂量化疗和移植后的辅助治疗。
